Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme IP is the asset of the pharmaceutical industry. The current ...
Repurposing and repositioning have gained considerable attention from a range of stakeholders, including NIH, academic institutions, pharmaceutical companies, and even some technology companies, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results